alexa Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure.
Bioinformatics & Systems Biology

Bioinformatics & Systems Biology

Metabolomics:Open Access

Author(s): Jankowska EA, Ponikowska B, Majda J, Zymlinski R, Trzaska M,

Abstract Share this page

Abstract BACKGROUND: In severe chronic heart failure (CHF) elevated serum levels of uric acid (UA) predict poor survival. This study investigates whether hyperuricaemia (defined as serum UA level > or = 6.5 mg/dL) extends its prognostic value on population with less advanced CHF. METHODS: We studied 119 consecutive patients with stable, mild-moderate CHF (88 men, age: 64+/-11 years, NYHA class I/II/III: 9/65/45, LVEF: 32+/-8\%). RESULTS: Serum UA level (mean: 6.2+/-2.0 mg/dL, range: 2.0-16.2 mg/dL) increased in parallel to CHF severity expressed as NYHA class (4.9+/-1.1 vs. 5.7+/-1.5 vs. 7.2+/-2.4 mg/dL, NYHA I vs. II vs. III; NYHA I, II vs. III, p<0.01), inversely correlated with peak oxygen consumption (r=-0.39, p<0.01) and LVEF (r=-0.31, p<0.01), but not with renal function (expressed as creatinine clearance calculated from Cockcroft-Gault formula; r=-0.14, p>0.1), and predicted inflammatory status as evidenced by the correlation with C-reactive protein (r=0.31, p=0.003). Hyperuricaemia was detected in 48 (40\%) patients. During follow-up (mean: 580+/-209 days, > 18 months in all survivors), 27 (23\%) patients died. Hyperuricaemia was related to impaired survival in univariate (HR 2.8, 95\%CI: 1.3-6.1, p=0.01) and multivariate analyses (adjusted for NYHA class and impaired renal function--the only mortality predictors in this population; p<0.05). The 18-month survival for CHF patients with hyperuricaemia was 71\% (95\% CI: 58-84\%) vs. 89\% (95\% CI: 81-96\%) in those with normal UA level (p=0.01). CONCLUSION: In patients with mild-moderate CHF, hyperuricaemia predicts exercise intolerance and inflammatory activation and is strongly and independently related to poor prognosis. Whether elevated serum UA level may become a novel therapeutic target in CHF, deserves further studies. This article was published in Int J Cardiol and referenced in Metabolomics:Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords